TEDOVA: Vaccine OSE2101 +/- Pembrolizumab As Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer.
Future Oncology(2024)
Key words
anti PD1,maintenance,OSE2101,pembrolizumab,platinum-sensitive,recurrent ovarian cancer,vaccine
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined